NCT05649722View on ClinicalTrials.gov

An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

May 11, 2023

Primary Completion Date

March 14, 2026

Study Completion Date

March 14, 2026

Conditions
Pulmonary HypertensionInterstitial Lung Disease
Interventions
DRUG

Treprostinil Palmitil Inhalation Powder

Oral inhalation using a capsule-based dry powder inhaler device.

DRUG

Placebo

Oral placebo inhalation using a capsule-based dry powder inhaler device.

Trial Locations (22)

2109

AUS005, Macquarie Park

4000

BEL002, Liège

8035

ESP010, Barcelona

13125

GER002, Berlin

14050

GER012, Berlin

15706

ESP009, Santiago de Compostela

20123

ITA004, Milan

20900

ITA002, Monza

33011

ESP007, Oviedo

35392

GER010, Giessen

45239

GER003, Essen

69126

GER006, Heidelberg

80131

ITA003, Napoli

81377

GER004, München

90127

ITA001, Palermo

C1280AEB

ARG003, Autonomus City of Buenos Aires

S2013KDS

ARG001, Rosario

01307

GER001, Dresden

07120

ESP003, Palma

08907

ESP005, Barcelona

G81 4DY

GBR003, Clydebank

S10 2JF

GBR001, Sheffield

All Listed Sponsors
lead

Insmed Incorporated

INDUSTRY

NCT05649722 - An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) | Biotech Hunter | Biotech Hunter